About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Latest Press Releases

Date Title and Summary
Toggle Summary 2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient RiskAdditional Presentations Include Positive Results from Genomic Health's First Liquid Biopsy Study in Breast Cancer
Toggle Summary Breast Cancer Research and Treatment Publishes Oncotype DX® DCIS Score™ Study Conducted in Canada
Largest Genomic Study in DCIS Shows Genomic Health's Oncotype DX Predicts Local Recurrence, Helps Personalise Treatment of Stage 0 Breast Cancer TORONTO , Aug. 20, 2015 /CNW/ - Genomic Health, Inc. (Nasdaq: GHDX) today announced that Breast Cancer Research and Treatment published results from a
Toggle Summary Breast Cancer Research and Treatment Publishes Oncotype DX® DCIS Score™ Study
Largest Genomic Study in DCIS Reconfirms Oncotype DX as Independent Predictor of Local Recurrence, Representing Breakthrough in Personalizing Treatment of Stage 0 Breast Cancer
Toggle Summary Joins My Breast Cancer Coach to Provide Newly Diagnosed Patients With Online Personalized Treatment Information
REDWOOD CITY, CA - October 8, 2009 - has joined with Genomic Health, Inc. and Breast Cancer Network of Strength to expand My Breast Cancer Coach , a unique online tool that provides patients with a personalized report of treatment options and questions to ask their doctor based on

Webcasts & Presentations


The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.